Immunohistochemistry Study Urothelial Carcinoma using Tumor Markers (EGFR, EMA and CD117)
الباحث الأول:
Ebtihal Chiad Abass1, Alaa Salah Jumaah2, Kaswer Musa Jaafar Altoriah3, Hawraa Sahib Al-Haddad4, Aseel Al-Quzweni5, Hussein Raof Alghaszali6, Najah R. Hadi7*
الباحثين الآخرين:
Ebtihal Chiad Abass1, Alaa Salah Jumaah2, Kaswer Musa Jaafar Altoriah3, Hawraa Sahib Al-Haddad4, Aseel Al-Quzweni5, Hussein Raof Alghaszali6, Najah R. Hadi7*
المجلة:
Sys Rev Pharm 2020; 11(4): 223 228
تاريخ النشر:
None
مختصر البحث:
ABSTRACT Submitted: 28.01.2020 The aim of the present is to determine the immunohistochemical expression of EGFR, EMA and CD117 in case of urinary bladder transitional cell carcinoma and their relation with staging of tumor and i…
ABSTRACT Submitted: 28.01.2020 The aim of the present is to determine the immunohistochemical expression of EGFR, EMA and CD117 in case of urinary bladder transitional cell carcinoma and their relation with staging of tumor and its impact on further prognosis. EGFR immunohistochemical study showing (61.5 %) positive in case of urinary bladder carcinoma with significant difference between staging of tumor (p value 0.019) with signification expression between low grade and high grade tumor with P value 0.002 (6.2%) positivity in high grade versus (15.4 %) positivity in low grade). EMA showing strong positivity in urothelial carcinoma 96.2% without significant difference between staging and grading of tumor with p valve of (0.57) and (0.227) respectively CD117 immunohistochemical study showing total positive cases of urinary bladder carcinoma of 69.2% with significant difference in comparison with staging and grading of tumor with (P-value=0.00) for each
